Search results for: 'engineering services defense sector'

This study analyzes the emergence of engineered antibody therapeutics for cancer, examining the factors driving their adoption. The limitations of monoclonal antibodies have led to an increasing demand for novel formats. Companies are developing multispecific antibodies, such as bispecifics and trispecifics, and antibody fragments, such as Fab and ...

23 Jun 2023  |  Global  |  Market Research

Global Tissue-engineered Skin Substitute Growth Opportunities

Breakthrough Technologies and Competitive Intensity Drive Innovation

Infographics

×

Rising incidents of burn injuries, road accidents, and other trauma injuries, along with increasing cases of chronic wounds, such as diabetic ulcers and venous ulcers, are boosting the global tissue-engineered skin substitutes (TESS) market. Moreover, the increasing number of surgical injuries, plastic surgeries, cosmetic surgeries, and other recon...

02 Sep 2025  |  Global  |  Technology Research

Technological Advances in Engineered Cell Therapies, Global, 2025–2029

Emerging Trends and Technologies in Engineered Cell Therapies

Infographics

×

Engineered cell therapies have become a revolutionary medical field, surpassing conventional methods such as systemic medications and prominent immunosuppression to provide long-lasting, programmable, and targeted treatments for complicated diseases. Recent technical developments in engineered cell therapies examine how the rapid growth of cell eng...

21 Mar 2025  |  Global  |  Market Research

Pharmaceutical Clinical Contract Peripheral Services, Global, 2025–2030

The CRO Industry is Witnessing Transformational Growth Due to Industry Convergence and an Increasing Reliance on the Functional Service Provider (FSP) Model

Infographics

×

As trial volumes normalize after the COVID-19 pandemic, pharma and biopharma companies are re-focusing on their drug development pipelines. As a result, the market has been creating an increasing number of clinical trial outsourcing opportunities for CROs, with these service providers also refining their processes to ensure better clinical trial tu...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) delivers provides strategic insights into breakthrough innovations shaping the future of healthcare, life sciences, and precision therapeutics. It highlights advances in AI-enabled diagnostics, metabolic reprogramming, small molecules, deep proteomics, RNA disco...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping drug discovery, diagnostics, and therapeutic delivery across oncology, infectious diseases, rare and metabolic disorders, neuromuscular and neurodegenerative conditions, diabetes, ophthalmol...

With the growing preference for a patient-centric care delivery approach, the pharma industry follows a robust step-by-step approach towards market commercialization, with a clear understanding of the market stakeholders, segments, as well as post-launch forecasts to create seamless go-to-market strategies. To cater to the ever-evolving market land...

The future of three-dimensional bioprinting (3DBP) and its transformation of the healthcare sector will be determined by the breadth and depth of its application potential, and its ability to unleash a whole new world of application segments. From printing a tissue or cells to developing human organs, 3DBP has demonstrated capability in the world o...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights across recent innovations cross immunotherapies, precision medicine, cancer treatment, cell engineering, liquid biopsy and AI-enabled drug discovery and development. The TOE also highlights recent advances in implantables, ophthalmology, neurop...